NorthWest Biotherapeutics Inc (NWBO)

[Roman516]

Opinions with no facts have no support
Per your comment
"NWBO is going to be deep into 2024 before they are going to be competitive in the U.S. NVCR is more focused on the rest of the indications that are expected in 2023 -- NSCLC, pancreatic, ovarian and brain metastasis indications are coming. Much larger revenue potential that GBM."
With all the current news publications, research results from Dr. Linda Liau and her team at UCLA and many other supporting factors, NWBO should be approved in the UK soon, months not years. As a result, there is a high probability that NWBO will in fact show positive growth with both revenue and profits. This should be enough to sustain NWBO both in the eye of the financial community, investment community, and other means to sustain NWBO. The good news is that there is a high probability that NWBO will be able to address DCVax-L outside of the UK. The best news is that there are leading indicators that when DCVax-L is added to other compounds, that DCVax-L be able to address other cancers besides nGBM and rGBM brain cancer. If in fact this is the case, all of your issues become mute and NWBO stock goes through the roof, IMPO.